The Board of Directors, on the recommendation of the Audit Committee of the Board, in its meeting held on Friday, 14th November, 2025 at 5:00 p.m. have considered and approved the following: ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 2.4 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved un-audited financial results for the quarter and half year ended 30th September 2025 along with a clean Limited Review Report from A. Sachdev & Co. For Q2 FY26, net revenue from operations rose about 3% YoY to Rs 5,020 lacs (from Rs 4,872 lacs), but profit after tax more than doubled to Rs 591 lacs (from Rs 292 lacs), pushing basic EPS to Rs 0.61 vs Rs 0.30. For H1 FY26, revenue grew to Rs 9,973 lacs from Rs 9,452 lacs, while PAT surged to Rs 1,182 lacs from Rs 504 lacs — a jump of roughly 135%. The profit boost came mainly from better cost control, as total expenses grew only 4% in H1 while revenue rose 4.5%, leading to a sharp improvement in margins. The company also reduced total borrowings (non-current borrowings fell from Rs 4,043 lacs to Rs 2,906 lacs), while continuing heavy capex with capital work-in-progress rising to Rs 7,770 lacs from Rs 5,608 lacs.
Strong PAT growth and margin expansion are positive signals for shareholders, though the sharp drop in cash balances (from Rs 1,385 lacs to Rs 94 lacs) due to capex and debt repayment may warrant a closer look at liquidity. Overall, the results indicate improving operational profitability.